Growth In The Pulmonary Or Respiratory Drug Delivery Market Is Being Driven By Role Of Rising Healthcare Expenditure In Fueling The Growth Of Focal Segmental Glomerulosclerosis (FSGS) Drugs
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Large Will The Pulmonary Or Respiratory Drug Delivery Market Be By 2030 Compared To Its 2026 Market Size?
The pulmonary or respiratory drug delivery market has experienced robust expansion over recent years. Its valuation is projected to escalate from $75.67 billion in 2025 to $82.23 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.7%. The impetus behind its historical growth stems from factors such as the increasing prevalence of asthma and COPD, broad acceptance of inhalers, an expansion in respiratory hospitals, enhancements in aerosol technologies, and the growth of homecare treatments.
The pulmonary or respiratory drug delivery market is projected to experience significant growth over the next few years. By 2030, its size is expected to reach $114.23 billion, achieving a compound annual growth rate (CAGR) of 8.6%. This anticipated expansion can be attributed to factors such as an aging population, increasing exposure to air pollution, advancements in digital inhalers, the expansion of homecare settings, and a rise in chronic respiratory conditions. Prominent trends for the forecast period include a growing adoption of inhalation-based drug delivery methods, an increased demand for home-based respiratory therapies, the expanding use of dry powder and metered dose inhalers, a wider approach to chronic respiratory disease management, and a heightened focus on developing patient-friendly delivery devices.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20939&type=smp
What Key Drivers Are Fueling The Growth Of The Pulmonary Or Respiratory Drug Delivery Market?
The expanding prevalence of pneumonia is projected to drive the growth of the pulmonary or respiratory drug delivery market in the foreseeable future. Pneumonia is characterized as a lung infection that causes inflammation within the air sacs, potentially leading them to fill with fluid or pus, and resulting in symptoms such as cough, fever, and difficulty breathing. Its increasing occurrence is influenced by factors including an aging population, compromised immune systems, other respiratory infections, air pollution, smoking, and the emergence of antibiotic-resistant bacteria. Pulmonary or respiratory drug delivery provides significant aid to pneumonia patients by directly administering medications like antibiotics, bronchodilators, or anti-inflammatory agents to the lungs. This direct targeting enables quicker and more potent treatment, effectively alleviating symptoms, diminishing inflammation, clearing infections, and improving overall respiratory function, ultimately fostering recovery and preventing complications. For instance, in December 2024, as per Clinical Trials Arena, a UK-based clinical research news platform, hospital admissions of Mycoplasma pneumoniae saw a substantial rise of 461% from October 2023 to February 2024, increasing from 110 to 617 admissions. Moreover, 20.2% of pneumonia cases were detected in children aged 0 to 4 years, 25.4% in children aged 5 to 9 years, and 17.5% in children aged 10 to 14 years, contributing 410 of the 650 cases reported. Consequently, the rising prevalence of pneumonia is a significant driver for the pulmonary or respiratory drug delivery market.
How Is The Pulmonary Or Respiratory Drug Delivery Market Organized By Segment Classification?
The pulmonary or respiratory drug delivery market covered in this report is segmented –
1) By Product: Formulation Type, Device Type
2) By Canister Type: Plain Canister, Coated Canister
3) By Application: Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis, Other Applications
4) By End-User: Hospitals, Clinics, Home Care Settings
Subsegments:
1) By Formulation Type: Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Nebulizers, Liquid Aerosols, Nasal Sprays
2) By Device Type: Inhalers (Manual and Digital), Nebulizers (Compressor, Ultrasonic, Mesh), Breath-Activated Devices, Spacer Devices, Nasal Drug Delivery Devices
What Trends Are Influencing The Pulmonary Or Respiratory Drug Delivery Market?
Major corporations engaged in the pulmonary or respiratory drug delivery market are channeling their efforts into technological advancements, such as complex drug delivery systems, designed to enhance the effectiveness of treatments and improve patient compliance. These sophisticated drug delivery systems are advanced technologies that improve the precise delivery and regulated release of therapeutic agents, ultimately leading to greater drug efficacy and better patient outcomes. As an illustration, in July 2023, Viatris Inc., a US-based healthcare company manufacturing generic and branded medicines, along with Kindeva Drug Delivery L.P., a US-based company providing drug delivery services, launched Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol. This inhalation aerosol, approved by the Food and Drug Administration, a US-based government agency, is notable as the first generic equivalent of AstraZeneca’s Symbicort. It is a metered-dose inhaler that combines budesonide and formoterol for addressing asthma and chronic obstructive pulmonary disease. It is made available in two potencies: 80 micrograms and 160 micrograms, each with 4.5 micrograms of formoterol.
Who Are The Industry Participants Involved In The Pulmonary Or Respiratory Drug Delivery Market?
Major companies operating in the pulmonary or respiratory drug delivery market are Merck & Co. Inc., Novartis AG, Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, 3M Company, Koninklijke Philips N.V., GlaxoSmithKline, Omron Corporation, Teva Pharmaceutical Industries Ltd., Aptar Pharma, Sumitomo Pharma America Inc., Chiesi Farmaceutici S.p.A., Cipla Inc., Boehringer Ingelheim GmbH, Kindeva Drug Delivery Limited, Nemera Group, Hovione, H And T Presspart Group, Vectura Group plc
Get The Full Pulmonary Or Respiratory Drug Delivery Market Report:
Where Is The Pulmonary Or Respiratory Drug Delivery Market Primarily Concentrated By Region?
North America was the largest region in the pulmonary or respiratory drug delivery market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary or respiratory drug delivery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Pulmonary Or Respiratory Drug Delivery Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Pulmonary Or Respiratory Drug Delivery Market 2026, By The Business Research Company
Pulmonary Drug Delivery Devices Market Report 2026
Pharmaceutical Drug Delivery Market Report 2026
https://www.thebusinessresearchcompany.com/report/pharmaceutical-drug-delivery-global-market-report
Respiratory Disease Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/respiratory-disease-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
